Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma
Authors:
Open Access
- 3 February 2021
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 21 (4) , 1
Abstract
The determination of biomarkers in the blood specific for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) is crucial for the selection of effective treatment strategies and the prediction of prognosis. The purpose of the present study was to analyze the differentially expressed genes (DEGs) in LUSC and LUAD from The Cancer Genome Atlas (TCGA) database. In order to identify the potential biomarkers for non‑small cell lung cancer (NSCLC) for clinical diagnosis, bioinformatics was used to analyze the DEGs of two subtypes of NSCLC, LUAD and LUSC. Exosomes were isolated from the serum of patients with LUAD or LUSC and identified using transmission electron microscopy, nanoparticle tracking analysis and western blot analysis. A total of four differential exosomal mRNAs were selected for validation with serum samples from 70 patients with NSCLC via reverse transcription‑quantitative polymerase chain reaction. Receiver operating characteristic curves were established to evaluate the clinical diagnostic value of four DEGs for patients with LUAD and LUSC. The analysis based on TCGA data revealed the DEGs in LUSC and LUAD: A total of 1,619 genes were differentially expressed in patients with LUSC and LUAD. DEGs analyzed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses revealed that inflammation‑related signaling pathways, such as complement pathways, and multiple autoimmune diseases, such as systemic lupus erythematosus and asthma were mainly enriched in LUAD. The cell cycle, Hippo signaling pathway, Rap1 signaling pathway and Wnt signaling pathway were the main signaling pathways enriched in LUSC. The combination of tumor protein P63 (TP63), keratin 5 (KRT5), CEA cell adhesion molecule 6 (CEACAM6) and surfactant protein B (SFTPB) improved the specificity and sensitivity in the diagnosis of different lung cancer subtypes. Exosomal TP63, KRT5, CEACAM6 and SFTPB mRNAs can thus be used as biomarkers to differentiate between LUSC and LUAD, and may provide a novel strategy for their differential diagnosis and treatment.Keywords
This publication has 72 references indexed in Scilit:
- Comparative marker analysis of extracellular vesicles in different human cancer typesJournal of Extracellular Vesicles, 2013
- Ipilimumab: its potential in non-small cell lung cancerTherapeutic Advances in Medical Oncology, 2011
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Bone morphogenetic protein receptors and signal transductionThe Journal of Biochemistry, 2009
- Genetic Defects in Surfactant Protein A2 Are Associated with Pulmonary Fibrosis and Lung CancerThe American Journal of Human Genetics, 2009
- Pathologic expression of MHC class II is driven by mitogen‐activated protein kinasesEuropean Journal of Immunology, 2007
- The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung CancerCancer Research, 2005
- CEACAM6 Is a Novel Biomarker in Pancreatic Adenocarcinoma and PanIN LesionsAnnals of Surgery, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001